Stockscreener 앱 받기
4.56
2.47%
0.11
시간 외 거래:
4.54
-0.02
-0.44%
전일 마감가:
$4.45
열려 있는:
$4.55
하루 거래량:
5.66M
Relative Volume:
2.05
시가총액:
$1.25B
수익:
$6.31M
순이익/손실:
$-99.93M
주가수익비율:
-12.87
EPS:
-0.3544
순현금흐름:
$-85.14M
1주 성능:
-1.08%
1개월 성능:
-4.80%
6개월 성능:
+61.13%
1년 성능:
+149.18%
1일 변동 폭
$4.31
$4.66
1주일 범위
$4.31
$4.715
52주 변동 폭
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.56 | 1.22B | 6.31M | -99.93M | -85.14M | -0.3544 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - Yahoo Finance
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Taysha (TSHA) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Taysha (TSHA) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Valuation Update: How correlated is Taysha Gene Therapies Inc to the S P5002026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value - marketscreener.com
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress in Trials - GuruFocus
Taysha Gene Therapies 10-K: $9.8M Revenue, $(0.34) EPS - TradingView
Rett gene therapy advances at Taysha Gene Therapies (TSHA) - Stock Titan
Taysha Gene Therapies reports full-year 2025 earnings and issues corporate update - Traders Union
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Net Loss $0.34 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Taysha Gene Therap Reports 2025 Full-Year Results — $9.8M Revenue, $109.0M Net Loss - TradingView
Taysha Gene Therapies (TSHA) deepens 2025 loss but advances Rett trial - Stock Titan
TSHA: TSHA-102 trials progressed with strong safety, regulatory alignment, and robust cash position - TradingView
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Needham Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 - The Manila Times
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - MSN
Jefferies Financial Group Inc. Sells 8,157,091 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
Aug Catalysts: How cyclical is Taysha Gene Therapies Incs revenue streamDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Reactions: What hedge funds are buying Taysha Gene Therapies IncTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Decliners Report: Is Taysha Gene Therapies Inc stock good for income investors2025 Winners & Losers & Weekly Top Performers Watchlists - baoquankhu1.vn
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Grants Stock Units and Options to N - GuruFocus
Taysha Gene Therapies announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Taysha hire granted 156,870 RSUs plus 134,460 options - Stock Titan
Highs Report: Is Taysha Gene Therapies Inc attractive for institutional investorsTrade Entry Summary & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Aug Update: Will Taysha Gene Therapies Inc benefit from AI trendsJuly 2025 Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
TSHA SEC FilingsTaysha Gene Therapies, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Taysha Gene Therapies (TSHA) and Zimmer Biomet Holdings (ZBH) - The Globe and Mail
TSHA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Taysha Gene faces earnings test as Rett trial advances By Investing.com - Investing.com Nigeria
Taysha Gene faces earnings test as Rett trial advances - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC - MarketBeat
TSHA: Needham Reiterates Buy Rating with Price Target Maintained - GuruFocus
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Taysha Gene Therapies Inc 주식 (TSHA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Alam Kamran | CHIEF FINANCIAL OFFICER |
Feb 04 '26 |
Sale |
4.52 |
1,655 |
7,481 |
1,442,131 |
1.20%
0.06%
자본화:
|
볼륨(24시간):